Perrigo (PRGO)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$14.92+4.56%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · PRGO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -39.4% |
| Our one-year growth estimate | diamond | -1.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 38.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 23 industry peers · Company calendar date is not available
PRGO — CEO transition
Dated 2026-07-06
Interim President and Chief Executive Officer — Albert A. Manzone: Mr. Manzone was appointed as the Interim President and Chief Executive Officer with detailed compensatory arrangements.
Why it matters: Earnings results will show if Perrigo can meet its full-year guidance after a challenging Q1.
Watch forQ2 earnings report shows adjusted EPS within the guided range of $2.00 to $2.30.
Also watch forQ2 earnings report shows adjusted EPS below the guided range.
Why it matters: Gaining market share can signal effective execution of the Three-S plan and drive revenue growth.
Supportive ifReported market share gains in the Self Care segment of at least 100 basis points.
Worry ifMarket share declines or stagnation in the Self Care segment.
Why it matters: Gaining market share shows the strategy is working. This can help the company earn more money.
Supportive ifReported market share gains in key categories, especially in U.S. Store Brand and Women’s Health.
Worry ifNo market share gains reported, or losses in key product categories.
Why it matters: Better margins mean better efficiency and cost control. This is key for making more money.
Supportive ifOperating margin improves from 2.3% in Q2 to above 4% in Q3.
Worry ifOperating margin drops below 2.3% in Q3.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$169 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $442 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,729 loss on $10,000 · 57.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Having a permanent CEO can stabilize leadership. This helps Perrigo's plans and builds investor trust.
Supportive ifA permanent CEO has been announced. This person matches Perrigo's strategic goals.
Worry ifInterim leadership continues for over six months. There is still no permanent appointment.
Why it matters: Reducing debt will help with finances and support growth plans.
Supportive ifDebt reduction of at least $359 million from the Dermacosmetics sale is done.
Worry ifNo significant debt reduction is reported in the next quarter.
Why it matters: Earnings results will show how well the company is doing and its trends.
Watch forEarnings beat expectations with revenue growth over 5%.
Also watch forEarnings miss expectations with revenue growth below 0%.
Why it matters: Better cash flow shows improved efficiency and stability. This is important for Perrigo's change.
Supportive ifOperating cash flow turns positive in Q2 2026.
Worry ifOperating cash flow remains negative in Q2 2026.
Why it matters: A new CEO can change the company's plans. This can affect how investors feel. Stability is important during this time.
Supportive ifAnnouncement of a permanent CEO who has a strong track record in consumer health.
Worry ifIf there is no permanent CEO in six months, uncertainty will continue.
Why it matters: Maintaining the dividend shows commitment to shareholders. A cut could signal deeper issues.
Supportive ifPerrigo maintains its dividend at $0.29 per share in Q2.
Worry ifPerrigo cuts the dividend below $0.29 per share.
Why it matters: Successful debt reduction improves financial health and frees up resources for growth. This is key for investor confidence.
Supportive ifPerrigo shows a big drop in total debt. This happened after selling the Dermacosmetics division.
Worry ifTotal debt does not change or goes up. This is despite selling parts to reduce debt.
Why it matters: Reducing debt helps with financial health and future investments.
Supportive ifManagement says total debt fell by at least $300 million after selling assets.
Worry ifTotal debt stays the same or goes up after selling assets.
Why it matters: Gains in market share indicate effective execution of the Three-S plan and could support revenue growth.
Supportive ifU.S. store brand OTC volume share increases by at least 100 basis points.
Worry ifU.S. store brand OTC volume share does not increase or declines.
Why it matters: Keeping guidance shows confidence in recovery and the Three-S plan.
Supportive ifManagement confirms full-year 2026 guidance. They expect All In net sales growth between -5.5% and -1.5%.
Worry ifManagement lowers full-year 2026 guidance. They expect All In net sales below -5.5%.
Why it matters: A decline worse than 3.5% would signal ongoing category softness and impact market share gains.
Worry ifCore net sales decline greater than 3.5% year over year in Q3.
Less concerning ifCore net sales decline less than or stabilize year over year.
Why it matters: Completing the acquisition may help Perrigo grow. It could also improve its market position.
Supportive ifThe acquisition closes on schedule and is confirmed in a press release.
Worry ifThe acquisition is postponed or called off.